This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Eli Lilly (LLY) Q2 Earnings Miss, Sales Beat, Stock Down
by Zacks Equity Research
Eli Lilly (LLY) reports mixed second-quarter results and ttightens 2021 sales forecast. Stock down in pre-market trading.
Earnings Preview: Vir Biotechnology, Inc. (VIR) Q2 Earnings Expected to Decline
by Zacks Equity Research
Vir Biotechnology, Inc. (VIR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Glaxo's (GSK) Q2 Earnings Beat, Revenues on Recovery Track
by Zacks Equity Research
Glaxo's (GSK) revenues benefit from recovery in sales of products across all segments and additional revenues from the supply of pandemic adjuvant to partners.
Glaxo (GSK) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Glaxo's (GSK) newer respiratory and HIV drugs are likely to have driven second-quarter sales. However, sales of vaccines are likely to have been hurt by COVID-19 vaccine prioritization.
Regeneron's (REGN) Antibody Cocktail for COVID-19 Approved in Japan
by Zacks Equity Research
Regeneron's(REGN) cocktail for the treatment of COVID-19 gets approval in Japan as Ronapreve.
Vir Biotech (VIR) Begins Dosing in Phase II Hepatitis B Study
by Zacks Equity Research
Vir Biotechnology (VIR) doses the first patient in a phase II study evaluating the combo of VIR-2218 plus VIR-3434 for treating patients with chronic hepatitis B virus infection.
Lilly (LLY) Stock Riding on Pipeline Developments This Year
by Zacks Equity Research
Lilly's (LLY) shares are up this year mainly due to positive developments related to its interesting pipeline of cancer, diabetes and Alzheimer's candidates.
Aridis' (ARDS) COVID Antibody Combo Neutralizes Delta Variant
by Zacks Equity Research
Aridis Pharmaceuticals' (ARDS) inhaled COVID-19 dual antibody cocktail treatment, AR-712, binds and neutralizes the Delta variant of the virus. Stock rises in after-hours trading.
Glaxo (GSK)/Vir Affirm COVID-19 Drug Cuts Hospitalization/Death
by Zacks Equity Research
Glaxo (GSK)/Vir Biotech's new data confirms that COVID-19 treatment, sotrovimab can cut hospitalization and risk of death. ViiV Healthcare inks deal with Halozyme to use its ENHANZE technology to make better HIV medicines.
Gilead (GILD) Veklury Data Positive in Hospitalized COVID Patients
by Zacks Equity Research
Gilead (GILD) announces positive data on Veklury in hospitalized patients with COVID-19 across three analyses of large retrospective real-world data sets.
Regeneron (REGN) Announces Data on COVID-19 Antibody Cocktail
by Zacks Equity Research
Regeneron (REGN) announces positive results from a phase III study on antibody cocktail, REGEN-COV.
Should You Invest in the ALPS Medical Breakthroughs ETF (SBIO)?
by Zacks Equity Research
Sector ETF report for SBIO
Vir Biotech (VIR)/Glaxo COVID-19 Drug Gets FDA Emergency Nod
by Zacks Equity Research
Glaxo (GSK)/VIR Biotech's (VIR) sotrovimab demonstrated an 85% reduction in hospitalization or death in a study evaluating it in high-risk COVID-19 patients.
Glaxo (GSK)/ Vir Biotech's COVID-19 Antibody Gets CHMP Nod
by Zacks Equity Research
The CHMP issues a positive scientific opinion on Glaxo (GSK) and partner Vir Biotech's antibody candidate, sotrovimab (VIR-7831), for the treatment of adults and adolescents with COVID-19 infection.
The Zacks Analyst Blog Highlights: GlaxoSmithKline, Sanofi, CureVac and Vir Biotechnology
by Zacks Equity Research
The Zacks Analyst Blog Highlights: GlaxoSmithKline, Sanofi, CureVac and Vir Biotechnology
Glaxo/Medicago COVID-19 Vaccine Shows Strong Immune Response
by Zacks Equity Research
Glaxo (GSK) and its partner Medicago's adjuvant COVID-19 vaccine candidate induces robust neutralizing antibody and cellular immune responses in mid-stage study participants.
Should You Invest in the ALPS Medical Breakthroughs ETF (SBIO)?
by Zacks Equity Research
Sector ETF report for SBIO
Vir Biotechnology, Inc. (VIR) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Vir Biotechnology, Inc. (VIR) delivered earnings and revenue surprises of -473.91% and -98.84%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Vir Biotechnology, Inc. (VIR) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Vir Biotechnology, Inc. (VIR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Eli Lilly (LLY) Q1 Earnings Miss, COVID-19 Drug Demand Low
by Zacks Equity Research
Lilly (LLY) misses first-quarter estimates for both earnings and sales. It narrows 2021 forecast. Stock down in pre-market trading.
What's in the Cards for Eli Lilly (LLY) This Earnings Season?
by Zacks Equity Research
Higher demand for its growth drugs is likely to have offset generic competition for several other drugs to boost Lilly's (LLY) first-quarter sales.
Lilly (LLY) to End Solo Bamlanivimab Use, Back COVID-19 Combo
by Zacks Equity Research
Lilly (LLY) plans to stop COVID-19 treatment with bamlanivimab alone in the United States. Instead, a combination of bamlanivimab and etesevimab will be available for the same, a better therapy for variants.
Glaxo (GSK)/ Vir Biotech COVID-19 Antibody Under Review in EU
by Zacks Equity Research
The EMA starts review of Glaxo (GSK) and partner Vir Biotech's antibody candidate, VIR-7831, for the treatment of adults and adolescents with COVID-19 infection.
Regeneron (REGN) Posts Positive Data on COVID-19 Antibody Cocktail
by Zacks Equity Research
Regeneron (REGN) announces encouraging data on antibody cocktail, REGEN-COV, from two phase III studies.
CytoDyn (CYDY) Files New Protocol With FDA for COVID-19 Study
by Zacks Equity Research
CytoDyn (CYDY) submits a new protocol with the regulatory body in the United States to study a higher dose of leronlimab for severely-infected COVID-19 patients.